Results 81 to 90 of about 138,439 (148)

Human flaws and logical tools in engineering

open access: yesThe Canadian Journal of Chemical Engineering, EarlyView.
Abstract This paper explores the limitations of human cognition, especially in engineering research, emphasizing the need for mathematical models and methods to guide decision‐making and theory validation. While human cognition excels in certain tasks, it is prone to biases that can distort our understanding.
André C. R. Martins
wiley   +1 more source

Noisy matrix completion for longitudinal data with subject‐ and time‐specific covariates

open access: yesCanadian Journal of Statistics, EarlyView.
Abstract In this article, we consider the imputation of missing responses in a longitudinal dataset via matrix completion. We propose a fixed‐effect, longitudinal, low‐rank model that incorporates both subject‐specific and time‐specific covariates. To solve the optimization problem, a two‐step optimization algorithm is proposed, which provides good ...
Zhaohan Sun, Yeying Zhu, Joel A. Dubin
wiley   +1 more source

Random discrete probability measures based on a negative binomial process

open access: yesCanadian Journal of Statistics, EarlyView.
Abstract A distinctive functional of the Poisson point process is the negative binomial process for which the increments are not independent but are independent conditional on an underlying gamma variable. Using a new point process representation for the negative binomial process, we generalize the Poisson–Kingman distribution and its corresponding ...
Sadegh Chegini, Mahmoud Zarepour
wiley   +1 more source

Novel 4,5‐Dihydrothiazole‐phenylpiperazine Derivatives: Synthesis, Docking Studies and Pharmacological Evaluation as Serotonergic Agents

open access: yesChemMedChem, Accepted Article.
We have described the synthesis of a new series of LCAPs (long‐chain arylpiperazine) as serotoninergic ligands (FG 1‐18). The combination of structural elements including heterocyclic nucleus, propyl chain and 4,5‐dihydrothiazol‐2‐ylphenylpiperazines, led to the preparation of different derivatives tested for their affinity toward 5‐HT1A, 5‐HT2A and 5 ...
Giorgia Andreozzi   +18 more
wiley   +1 more source

Ten quick tips to get you started with Bayesian statistics. [PDF]

open access: yesPLoS Comput Biol
Gimenez O, Royle A, Kéry M, Nater CR.
europepmc   +1 more source

Modeling and Simulation to Inform Apixaban Dosing in Pediatrics With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Treated With Asparaginase

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Apixaban could be a potential treatment option for the prevention of venous thromboembolism (VTE) in children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). This analysis describes an updated two‐compartment population pharmacokinetic (PPK) model that characterizes the PK variability of apixaban in pediatric patients with ALL ...
Praneeth Jarugula   +14 more
wiley   +1 more source

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development (MIDD) integrates data to quantify benefit/risk informing objective drug discovery and development decisions. An additional critical benefit of MIDD is postulated to be improvement in trial and program efficiencies. While the application of MIDD has grown, there have been no clear examples across programs to demonstrate ...
Vaishali Sahasrabudhe   +4 more
wiley   +1 more source

Dose Selection for DuoBody®‐CD40x4‐1BB (GEN1042/BNT312) Using a mPBPK/RO Model Leveraging Preclinical and Clinical Data

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Optimizing target engagement for bispecific antibodies (bsAbs) is challenging, as bsAbs bind to two different targets in vivo to form a trimolecular complex (trimer), and likely display a bell‐shaped concentration–response curve. bsAbs trimer formation is expected to be related to efficacy and safety, and determining the dose level at which it is ...
Gaurav Bajaj   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy